跳至主要内容
临床试验/NCT02510261
NCT02510261已完成3 期

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study

Alnylam Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 211 人开始时间: 2015年7月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
211
试验地点
1
主要终点
Percentage of Participants With Adverse Events (AEs) Leading to Study Discontinuation

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
  • Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent

排除标准

  • Any new or uncontrolled condition that could make the participant unsuitable for participation

研究组 & 干预措施

Prior Placebo Group of Study 004

Experimental

Participants who received placebo and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 milligrams per kilogram (mg/kg) patisiran intravenously (IV) once every 3 weeks (Q3W) up to 65.5 months.

干预措施: Patisiran (Drug)

Prior Patisiran Group of Study 004

Experimental

Participants who received patisiran and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 66.9 months.

干预措施: Patisiran (Drug)

Prior Patisiran Group of Study 003

Experimental

Participants who received patisiran and completed parent study ALN-TTR02-003 (NCT01961921) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 61.4 months.

干预措施: Patisiran (Drug)

结局指标

主要结局

Percentage of Participants With Adverse Events (AEs) Leading to Study Discontinuation

时间窗: First dose up to 28 days after last dose of study drug (approximately 5.6 years)

AE is any untoward medical occurrence in a participant or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

次要结局

  • Change From Baseline in the Total Modified NIS (mNIS +7) Composite Score At Year 3(Baseline, Year 3)
  • Change From Baseline in the NIS+7 Total Score at Week 52(Baseline, Week 52)
  • Change From Baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) Questionnaire Total Score at Year 5(Baseline, Year 5)
  • Change From Baseline in the Total Neuropathy Impairment Score (NIS) at Year 5(Baseline, Year 5)
  • Change From Baseline in the EuroQOL-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Year 5(Baseline, Year 5)
  • Change From Baseline in the EuroQoL Visual Analogue Scale (EQ-VAS) Score at Year 5(Baseline, Year 5)
  • Change From Baseline in the Composite Autonomic Symptom Score (COMPASS 31) Total Score at Week 52(Baseline, Week 52)
  • Change From Baseline in the Modified Body Mass Index (mBMI) at Year 5(Baseline, Year 5)
  • Change From Baseline in the Rasch-built Overall Disability Scale (R-ODS) at Year 5(Baseline, Year 5)
  • Change From Baseline in the NIS+7 Component: NIS-Weakness (NIS-W) Score at Year 5(Baseline, Year 5)
  • Change From Baseline in the 10-meter Walk Test (10-MWT) Speed at Year 5(Baseline, Year 5)
  • Change From Baseline in the Hand Grip Strength at Week 52(Baseline, Week 52)
  • Number of Participants With Change From Baseline in the Polyneuropathy Disability (PND) Stage(Baseline, Year 5)
  • Number of Participants With Change From Baseline in the Familial Amyloidotic Polyneuropathy (FAP) Stage(Baseline, Year 5)
  • Number of Participants With Change From Baseline in the New York Heart Association (NYHA) Classification(Baseline, Year 5)
  • Change From Baseline in the Intraepidermal Nerve Fiber Density (IENFD) at Year 5(Baseline, Year 5)
  • Change From Baseline in the Sweat Gland Nerve Fiber Density (SGNFD) at Year 5(Baseline, Year 5)
  • Change From Baseline in the Dermal Amyloid Burden at Year 5(Baseline, Year 5)
  • Change From Baseline in the Cardiac Biomarker: Serum Troponin I at Year 5(Baseline, Year 5)
  • Change From Baseline in the Cardiac Biomarker: N-terminal Prohormone of B-type Natriuretic Peptide (NT-proBNP) at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: Average Peak Longitudinal Strain at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: Left Ventricular (LV) Mass at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: LV End-diastolic Volume at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: LV Relative Wall Thickness at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: Mean LV Wall Thickness at Year 5(Baseline, Year 5)
  • Change From Baseline in the Echocardiogram Parameter: Cardiac Output at Year 5(Baseline, Year 5)
  • Percent Change From Baseline in Serum TTR Levels at Year 5(Baseline, Year 5)

研究者

发起方
Alnylam Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验